{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:51:28Z","timestamp":1785783088639,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-Nanji-Ippan-010"],"award-info":[{"award-number":["H29-Nanji-Ippan-010"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K07890"],"award-info":[{"award-number":["JP18K07890"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.braindev.2019.02.010","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T09:42:04Z","timestamp":1551346924000},"page":"516-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum carnitine levels of children with epilepsy: Related factors including valproate"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2447-2857","authenticated-orcid":false,"given":"Akihisa","family":"Okumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-5815","authenticated-orcid":false,"given":"Hideyuki","family":"Iwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-772X","authenticated-orcid":false,"given":"Shingo","family":"Numoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2019.02.010_b0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0b013e3181fe3953","article-title":"Acute encephalopathy in a child with secondary carnitine deficiency due to pivalate-conjugated antibiotics","volume":"30","author":"Okumura","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.braindev.2019.02.010_b0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2016.02.080","article-title":"Clinical features of carnitine deficiency secondary to pivalate-conjugated antibiotic therapy","volume":"173","author":"Kobayashi","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2019.02.010_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s005990050060","article-title":"Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs","volume":"29","author":"Verrotti","year":"1999","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.braindev.2019.02.010_b0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.braindev.2005.11.005","article-title":"Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet","volume":"28","author":"Coppola","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2019.02.010_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.braindev.2019.02.010_b0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1469-8749.1991.tb14963.x","article-title":"Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs","volume":"33","author":"Thom","year":"1991","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2019.02.010_b0035","first-page":"999","article-title":"The effect of valproic acid on plasma carnitine levels","volume":"145","author":"Opala","year":"1991","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.braindev.2019.02.010_b0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073808321060","article-title":"Serum and muscle carnitine levels in epileptic children receiving sodium valproate","volume":"24","author":"Anil","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2019.02.010_b0045","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/clinchem\/40.5.817","article-title":"Carnitine determination by an enzymatic cycling method with carnitine dehydrogenase","volume":"40","author":"Takahashi","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.braindev.2019.02.010_b0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.braindev.2019.02.010_b0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.braindev.2014.12.004","article-title":"Carnitine deficiency: Risk factors and incidence in children with epilepsy","volume":"37","author":"Fukuda","year":"2015","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2019.02.010_b0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0887-8994(02)00460-5","article-title":"Carnitine level in Chinese epileptic patients taking sodium valproate","volume":"28","author":"Fung","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2019.02.010_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ridd.2014.11.020","article-title":"Nutritional deficiencies and overweight prevalence among children with autism spectrum disorder","volume":"38","author":"Shmaya","year":"2015","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.braindev.2019.02.010_b0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijdevneu.2016.07.003","article-title":"Feeding behavior and dietary intake of male children and adolescents with autism spectrum disorder: a case-control study","volume":"53","author":"Castro","year":"2016","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.braindev.2019.02.010_b0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0006-2952(96)00507-2","article-title":"Inhibition of carnitine biosynthesis by valproic acid in rats\u2013the biochemical mechanism of inhibition","volume":"52","author":"Farkas","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.braindev.2019.02.010_b0080","doi-asserted-by":"crossref","DOI":"10.1542\/peds.101.5.e9","article-title":"Valproate therapy does not deplete carnitine levels in otherwise healthy children","volume":"101","author":"Hirose","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.braindev.2019.02.010_b0085","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.braindev.2010.12.003","article-title":"Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS\/MS","volume":"33","author":"Nakajima","year":"2011","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2019.02.010_b0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.1996.tb14058.x","article-title":"The effect of carnitine supplementation in valproate-induced hyperammonaemia","volume":"85","author":"B\u00f6hles","year":"1996","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.braindev.2019.02.010_b0095","first-page":"1","article-title":"Levocarnitine for the treatment of valproic acid\u2013induced hyperammonemic encephalopathy in children: the experience of large, tertiary care pediatric hospital and a poison center","author":"Glatstein","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.braindev.2019.02.010_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008117","article-title":"Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report","volume":"96","author":"Cattaneo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.braindev.2019.02.010_b0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pediatrneurol.2016.12.011","article-title":"Burst suppression pattern on electroencephalogram secondary to valproic acid-induced hyperammonemic encephalopathy","volume":"73","author":"Cherian","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.braindev.2019.02.010_b0110","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0300060517703278","article-title":"L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: a case report","volume":"45","author":"Maldonado","year":"2017","journal-title":"J Int Med Res"},{"key":"10.1016\/j.braindev.2019.02.010_b0115","first-page":"6242314","article-title":"Valproic acid induced hyperammonemia in a long time treated patient","volume":"2016","author":"Aiyer","year":"2016","journal-title":"Case Rep Psychiatry"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418306430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418306430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:15:23Z","timestamp":1778692523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760418306430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0387760418306430"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2019.02.010","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum carnitine levels of children with epilepsy: Related factors including valproate","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2019.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}